10 years of Nahyco® technology celebrated at IMCAS 2025

Also this year, IBSA Derma – IBSA’s aesthetic medicine division – participated in the 26^th edition of the IMCAS World Congress (International Master Course on Aging Science), held in Paris from January 30 to February 1.

IMCAS is the leading international event in the field of aesthetic medicine, dermatology and plastic surgery, and this year saw the participation of over 20,000 experts. 

As in past editions, IBSA organised two symposiums and participated in a round table on the future of aesthetic medicine; the congress was also an opportunity to celebrate an important milestone.

10 YEARS OF INNOVATION: NAHYCO® TECHNOLOGY

IMCAS was the ideal context to celebrate 10 years of NAHYCO® technology, the basis of the Profhilo® line products, which represents an innovation in the world of hyaluronic acid synthesis. This technology consists of a thermal process that leads to cooperative hybrid complexes of hyaluronic acid (HCC) which have application in the area of ​​facial and body tissue regeneration¹. 

THE SYMPOSIUM FOR AN AESTHETIC AND REGENERATIVE MEDICINE

At IMCAS, IBSA confirmed itself among the leading companies in promoting the concept of authentic beauty, based on innovative aesthetic medicine, capable of encouraging an ethical approach.

The symposium organised by IBSA was entitled The future of Tissue Regeneration with NAHYCO® Technology. Feeling and seeing results. Some of the major international experts in aesthetic medicine participated in the event, exploring various topics. Among these, Dr S. Liew presented clinical evidence highlighting the regenerative properties of hybrid cooperative complexes of hyaluronic acid: HCC treatment showed promising results in tissue repair, demonstrating a potential role in regenerative medicine².

FUTURE TRENDS: REGENERATIVE MEDICINE

During the congress, a round table between representatives of the main companies in the sector was also held. Chief Commercial Officer Luca Crippa – who participated for IBSA – said: 

“I believe the future of aesthetic medicine will focus on the area of longevity and regenerative medicine. Today, we see this trend in the field of bio-remodelling products. And we are only at the beginning. In my opinion, in the future aesthetic medicine will be increasingly focused on the concept of health as a whole, with the aim of achieving a youthfulness of being, rather than just focusing on appearance”.

IBSA’s commitment in the field of regenerative medicine dates back to 2015 and has been consolidated over the years to offer treatments that favour the process of skin remodelling relying on physiological means. With this in mind, IBSA will continue to invest in technology and innovation to respond increasingly effectively to the needs of doctors and patients.

1. Humzah D, Molina B, Salti G, Cigni C, Bellia G, Grimolizzi F. Intradermal Injection of Hybrid Complexes of High- and Low-Molecular-Weight Hyaluronan: Where Do We Stand and Where Are We Headed in Regenerative Medicine? Int J Mol Sci. 2024 Mar 12;25(6):3216.

2. D'Agostino A, Stellavato A, Busico T, Papa A, Tirino V, Papaccio G, La Gatta A, De Rosa M, Schiraldi C. In vitro analysis of the effects on wound healing of high- and low-molecular weight chains of hyaluronan and their hybrid H-HA/L-HA complexes. BMC Cell Biol. 2015 Jul 11;16:19.